Practical management of oligometastatic gastric cancer
Open Access
- 21 November 2024
- journal article
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 6
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerJAMA, 2023
- Long‐term treatment outcomes in gastric cancer with oligometastasisAnnals of Gastroenterological Surgery, 2023
- Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal CancerJAMA Network Open, 2022
- International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)Annals of Gastroenterological Surgery, 2021
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric CancerJAMA Oncology, 2020
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerJAMA Oncology, 2017
- Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastasesBritish Journal of Surgery, 2015
- Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasisBritish Journal of Surgery, 2014
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993